MersV1, PubMed, Curation, bibRecord, 000598

Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.

Identifieur interne : 000598 ( PubMed/Curation ); précédent : 000597; suivant : 000599

Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.

Auteurs : Reham A. Al Kahlout [Qatar] ; Gheyath K. Nasrallah [Qatar] ; Elmoubasher A. Farag [Qatar] ; Lingshu Wang [États-Unis] ; Erik Lattwein [Allemagne] ; Marcel A. Müller [Allemagne] ; Mohamed E. El Zowalaty [Afrique du Sud] ; Hamad E. Al Romaihi [Qatar] ; Barney S. Graham [États-Unis] ; Asmaa A. Al Thani [Qatar] ; Hadi M. Yassine [Qatar]

Source :

Journal of immunology research [ 2314-7156 ] ; 2019.

RBID : pubmed:30906787

Descripteurs français

KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Anticorps antiviraux (sang), Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Faux positifs, Femelle, Groupes de population, Humains, Infections à coronavirus (immunologie), Jeune adulte, Mâle, Prévalence, Qatar, Risque, Réactions croisées, Sujet âgé, Sérologie.
MESH :
- immunologie : Coronavirus du syndrome respiratoire du Moyen-Orient, Infections à coronavirus.
- sang : Anticorps antiviraux.
- Adolescent, Adulte, Adulte d'âge moyen, Faux positifs, Femelle, Groupes de population, Humains, Jeune adulte, Mâle, Prévalence, Qatar, Risque, Réactions croisées, Sujet âgé, Sérologie.
Wicri :
- geographic : Qatar.

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Antibodies, Viral (blood), Coronavirus Infections (immunology), Cross Reactions, False Positive Reactions, Female, Humans, Male, Middle Aged, Middle East Respiratory Syndrome Coronavirus (immunology), Population Groups, Prevalence, Qatar, Risk, Serology, Young Adult.
MESH :
- chemical , blood : Antibodies, Viral.
- geographic : Qatar.
- immunology : Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus.
- Adolescent, Adult, Aged, Cross Reactions, False Positive Reactions, Female, Humans, Male, Middle Aged, Population Groups, Prevalence, Risk, Serology, Young Adult.

Abstract

Infection with Middle East respiratory syndrome coronavirus (MERS-CoV) could be asymptomatic or cause mild influenza-like illness. Therefore, the prevalence of MERS-CoV infections in the general population could be underestimated, which necessitates active surveillance to determine the epidemiological importance of asymptomatic cases. The aim of this study is to evaluate the performance of various serological assays and to estimate the seroprevalence of anti-MERS-CoV antibodies in high- and low-risk groups in Qatar. A total of 4858 samples were screened, including 4719 samples collected from healthy blood donors (BD) over a period of five years (2012-2016), 135 samples from baseline case contacts (CC) collected from individuals in close contact with three positive PCR-confirmed patients (CP), and four samples from MERS-CoV CP. Initial screening using anti-MERS-CoV IgG (IgG rS1-ELISA kit) revealed ten reactive samples from BD (10/4719, 0.21%), one from CC (1/135, 0.74%), and three from CP (3/4, 75%). Samples from CP but not from BD were also reactive by whole-virus anti-MERS-CoV IgG (n = 3/4) and IgM (n = 1/4) indirect immunefluorescent tests (IIFT) and pseudoparticle neutralization test (ppNT). The reactive sample from CC was also confirmed by ppNT. Surprisingly, one out of thirteen (7.7%) randomly selected IgG rS1-ELISA-negative BD samples from the initial screening was reactive by the IgM-IIFT (but not by the IgG-IIFT) and was subsequently confirmed by ppNT. All IgG rS1-ELISA-reactive samples from BD exhibited considerable reactivity to the four circulating human coronaviruses (HKU1, OC43, 229E, and NL63). Cross-reactivity with SARS was only reported for samples from CP using IgG and IgM-IIFT. In conclusion, we report a low prevalence of anti-MERS antibodies in the general population, which coincides with the low number of all reported cases by the time of our study (2017) in Qatar (n = 21). The false-positive results and the observed cross-reactivity between MERS-CoV and other circulating human coronavirus necessitate more detailed evaluation of available serological assays.

DOI: 10.1155/2019/1386740
PubMed: 30906787

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000598

Links to Exploration step

pubmed:30906787

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.</title>
<author><name sortKey="Al Kahlout, Reham A" sort="Al Kahlout, Reham A" uniqKey="Al Kahlout R" first="Reham A" last="Al Kahlout">Reham A. Al Kahlout</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nasrallah, Gheyath K" sort="Nasrallah, Gheyath K" uniqKey="Nasrallah G" first="Gheyath K" last="Nasrallah">Gheyath K. Nasrallah</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Farag, Elmoubasher A" sort="Farag, Elmoubasher A" uniqKey="Farag E" first="Elmoubasher A" last="Farag">Elmoubasher A. Farag</name>
<affiliation wicri:level="1"><nlm:affiliation>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wang, Lingshu" sort="Wang, Lingshu" uniqKey="Wang L" first="Lingshu" last="Wang">Lingshu Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lattwein, Erik" sort="Lattwein, Erik" uniqKey="Lattwein E" first="Erik" last="Lattwein">Erik Lattwein</name>
<affiliation wicri:level="1"><nlm:affiliation>Euroimmun AG, Luebeck, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Euroimmun AG, Luebeck</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Muller, Marcel A" sort="Muller, Marcel A" uniqKey="Muller M" first="Marcel A" last="Müller">Marcel A. Müller</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Virology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Virology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="El Zowalaty, Mohamed E" sort="El Zowalaty, Mohamed E" uniqKey="El Zowalaty M" first="Mohamed E" last="El Zowalaty">Mohamed E. El Zowalaty</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology and Microbiology Research Laboratory, School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Virology and Microbiology Research Laboratory, School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Al Romaihi, Hamad E" sort="Al Romaihi, Hamad E" uniqKey="Al Romaihi H" first="Hamad E" last="Al Romaihi">Hamad E. Al Romaihi</name>
<affiliation wicri:level="1"><nlm:affiliation>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Graham, Barney S" sort="Graham, Barney S" uniqKey="Graham B" first="Barney S" last="Graham">Barney S. Graham</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Al Thani, Asmaa A" sort="Al Thani, Asmaa A" uniqKey="Al Thani A" first="Asmaa A" last="Al Thani">Asmaa A. Al Thani</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yassine, Hadi M" sort="Yassine, Hadi M" uniqKey="Yassine H" first="Hadi M" last="Yassine">Hadi M. Yassine</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30906787</idno>
<idno type="pmid">30906787</idno>
<idno type="doi">10.1155/2019/1386740</idno>
<idno type="wicri:Area/PubMed/Corpus">000598</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000598</idno>
<idno type="wicri:Area/PubMed/Curation">000598</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000598</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.</title>
<author><name sortKey="Al Kahlout, Reham A" sort="Al Kahlout, Reham A" uniqKey="Al Kahlout R" first="Reham A" last="Al Kahlout">Reham A. Al Kahlout</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nasrallah, Gheyath K" sort="Nasrallah, Gheyath K" uniqKey="Nasrallah G" first="Gheyath K" last="Nasrallah">Gheyath K. Nasrallah</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Farag, Elmoubasher A" sort="Farag, Elmoubasher A" uniqKey="Farag E" first="Elmoubasher A" last="Farag">Elmoubasher A. Farag</name>
<affiliation wicri:level="1"><nlm:affiliation>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wang, Lingshu" sort="Wang, Lingshu" uniqKey="Wang L" first="Lingshu" last="Wang">Lingshu Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lattwein, Erik" sort="Lattwein, Erik" uniqKey="Lattwein E" first="Erik" last="Lattwein">Erik Lattwein</name>
<affiliation wicri:level="1"><nlm:affiliation>Euroimmun AG, Luebeck, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Euroimmun AG, Luebeck</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Muller, Marcel A" sort="Muller, Marcel A" uniqKey="Muller M" first="Marcel A" last="Müller">Marcel A. Müller</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Virology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Virology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="El Zowalaty, Mohamed E" sort="El Zowalaty, Mohamed E" uniqKey="El Zowalaty M" first="Mohamed E" last="El Zowalaty">Mohamed E. El Zowalaty</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology and Microbiology Research Laboratory, School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Virology and Microbiology Research Laboratory, School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Al Romaihi, Hamad E" sort="Al Romaihi, Hamad E" uniqKey="Al Romaihi H" first="Hamad E" last="Al Romaihi">Hamad E. Al Romaihi</name>
<affiliation wicri:level="1"><nlm:affiliation>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Graham, Barney S" sort="Graham, Barney S" uniqKey="Graham B" first="Barney S" last="Graham">Barney S. Graham</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Al Thani, Asmaa A" sort="Al Thani, Asmaa A" uniqKey="Al Thani A" first="Asmaa A" last="Al Thani">Asmaa A. Al Thani</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yassine, Hadi M" sort="Yassine, Hadi M" uniqKey="Yassine H" first="Hadi M" last="Yassine">Hadi M. Yassine</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</nlm:affiliation>
<country xml:lang="fr">Qatar</country>
<wicri:regionArea>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of immunology research</title>
<idno type="eISSN">2314-7156</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Antibodies, Viral (blood)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Cross Reactions</term>
<term>False Positive Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Population Groups</term>
<term>Prevalence</term>
<term>Qatar</term>
<term>Risk</term>
<term>Serology</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Anticorps antiviraux (sang)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Faux positifs</term>
<term>Femelle</term>
<term>Groupes de population</term>
<term>Humains</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Prévalence</term>
<term>Qatar</term>
<term>Risque</term>
<term>Réactions croisées</term>
<term>Sujet âgé</term>
<term>Sérologie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Qatar</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Cross Reactions</term>
<term>False Positive Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Population Groups</term>
<term>Prevalence</term>
<term>Risk</term>
<term>Serology</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Faux positifs</term>
<term>Femelle</term>
<term>Groupes de population</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Prévalence</term>
<term>Qatar</term>
<term>Risque</term>
<term>Réactions croisées</term>
<term>Sujet âgé</term>
<term>Sérologie</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Qatar</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Infection with Middle East respiratory syndrome coronavirus (MERS-CoV) could be asymptomatic or cause mild influenza-like illness. Therefore, the prevalence of MERS-CoV infections in the general population could be underestimated, which necessitates active surveillance to determine the epidemiological importance of asymptomatic cases. The aim of this study is to evaluate the performance of various serological assays and to estimate the seroprevalence of anti-MERS-CoV antibodies in high- and low-risk groups in Qatar. A total of 4858 samples were screened, including 4719 samples collected from healthy blood donors (BD) over a period of five years (2012-2016), 135 samples from baseline case contacts (CC) collected from individuals in close contact with three positive PCR-confirmed patients (CP), and four samples from MERS-CoV CP. Initial screening using anti-MERS-CoV IgG (IgG rS1-ELISA kit) revealed ten reactive samples from BD (10/4719, 0.21%), one from CC (1/135, 0.74%), and three from CP (3/4, 75%). Samples from CP but not from BD were also reactive by whole-virus anti-MERS-CoV IgG (<i>n</i>
 = 3/4) and IgM (<i>n</i>
 = 1/4) indirect immunefluorescent tests (IIFT) and pseudoparticle neutralization test (ppNT). The reactive sample from CC was also confirmed by ppNT. Surprisingly, one out of thirteen (7.7%) randomly selected IgG rS1-ELISA-negative BD samples from the initial screening was reactive by the IgM-IIFT (but not by the IgG-IIFT) and was subsequently confirmed by ppNT. All IgG rS1-ELISA-reactive samples from BD exhibited considerable reactivity to the four circulating human coronaviruses (HKU1, OC43, 229E, and NL63). Cross-reactivity with SARS was only reported for samples from CP using IgG and IgM-IIFT. In conclusion, we report a low prevalence of anti-MERS antibodies in the general population, which coincides with the low number of all reported cases by the time of our study (2017) in Qatar (<i>n</i>
 = 21). The false-positive results and the observed cross-reactivity between MERS-CoV and other circulating human coronavirus necessitate more detailed evaluation of available serological assays.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30906787</PMID>
<DateCompleted><Year>2019</Year>
<Month>06</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>02</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>2019</Volume>
<PubDate><Year>2019</Year>
</PubDate>
</JournalIssue>
<Title>Journal of immunology research</Title>
<ISOAbbreviation>J Immunol Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.</ArticleTitle>
<Pagination><MedlinePgn>1386740</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2019/1386740</ELocationID>
<Abstract><AbstractText>Infection with Middle East respiratory syndrome coronavirus (MERS-CoV) could be asymptomatic or cause mild influenza-like illness. Therefore, the prevalence of MERS-CoV infections in the general population could be underestimated, which necessitates active surveillance to determine the epidemiological importance of asymptomatic cases. The aim of this study is to evaluate the performance of various serological assays and to estimate the seroprevalence of anti-MERS-CoV antibodies in high- and low-risk groups in Qatar. A total of 4858 samples were screened, including 4719 samples collected from healthy blood donors (BD) over a period of five years (2012-2016), 135 samples from baseline case contacts (CC) collected from individuals in close contact with three positive PCR-confirmed patients (CP), and four samples from MERS-CoV CP. Initial screening using anti-MERS-CoV IgG (IgG rS1-ELISA kit) revealed ten reactive samples from BD (10/4719, 0.21%), one from CC (1/135, 0.74%), and three from CP (3/4, 75%). Samples from CP but not from BD were also reactive by whole-virus anti-MERS-CoV IgG (<i>n</i>
 = 3/4) and IgM (<i>n</i>
 = 1/4) indirect immunefluorescent tests (IIFT) and pseudoparticle neutralization test (ppNT). The reactive sample from CC was also confirmed by ppNT. Surprisingly, one out of thirteen (7.7%) randomly selected IgG rS1-ELISA-negative BD samples from the initial screening was reactive by the IgM-IIFT (but not by the IgG-IIFT) and was subsequently confirmed by ppNT. All IgG rS1-ELISA-reactive samples from BD exhibited considerable reactivity to the four circulating human coronaviruses (HKU1, OC43, 229E, and NL63). Cross-reactivity with SARS was only reported for samples from CP using IgG and IgM-IIFT. In conclusion, we report a low prevalence of anti-MERS antibodies in the general population, which coincides with the low number of all reported cases by the time of our study (2017) in Qatar (<i>n</i>
 = 21). The false-positive results and the observed cross-reactivity between MERS-CoV and other circulating human coronavirus necessitate more detailed evaluation of available serological assays.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Al Kahlout</LastName>
<ForeName>Reham A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y" EqualContrib="Y"><LastName>Nasrallah</LastName>
<ForeName>Gheyath K</ForeName>
<Initials>GK</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Biomedical Research Center, Qatar University, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Farag</LastName>
<ForeName>Elmoubasher A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo><Affiliation>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Lingshu</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lattwein</LastName>
<ForeName>Erik</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Euroimmun AG, Luebeck, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Müller</LastName>
<ForeName>Marcel A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>Institute of Virology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>El Zowalaty</LastName>
<ForeName>Mohamed E</ForeName>
<Initials>ME</Initials>
<Identifier Source="ORCID">0000-0002-1056-4761</Identifier>
<AffiliationInfo><Affiliation>Virology and Microbiology Research Laboratory, School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000, South Africa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Al Romaihi</LastName>
<ForeName>Hamad E</ForeName>
<Initials>HE</Initials>
<AffiliationInfo><Affiliation>Communicable Diseases Control Programs, Public Health Department, Ministry of Public Health, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Graham</LastName>
<ForeName>Barney S</ForeName>
<Initials>BS</Initials>
<AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Al Thani</LastName>
<ForeName>Asmaa A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Biomedical Research Center, Qatar University, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yassine</LastName>
<ForeName>Hadi M</ForeName>
<Initials>HM</Initials>
<Identifier Source="ORCID">0000-0001-7592-2788</Identifier>
<AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Biomedical Research Center, Qatar University, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>02</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Egypt</Country>
<MedlineTA>J Immunol Res</MedlineTA>
<NlmUniqueID>101627166</NlmUniqueID>
<ISSNLinking>2314-7156</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D044382" MajorTopicYN="Y">Population Groups</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011780" MajorTopicYN="N" Type="Geographic">Qatar</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012699" MajorTopicYN="N">Serology</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>09</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>11</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>12</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>3</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>3</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30906787</ArticleId>
<ArticleId IdType="doi">10.1155/2019/1386740</ArticleId>
<ArticleId IdType="pmc">PMC6398027</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 1990 Jun;64(6):3112-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2159566</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2012 Sep 27;17(39):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23041020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2012 Dec 06;17(49):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23231891</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2012 Dec 06;17(49):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23231892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2013 Aug;67(2):130-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23583636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013 Apr 04;18(14):20441</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23594517</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2013 Jul 12;62(27):557</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23842446</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2014 Apr 1;209(7):995-1006</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24253287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Feb;14(2):140-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24355866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Aug;20(8):1339-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25075761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Aug 28;371(9):828-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25162889</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014 Oct 09;19(40):20923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25323078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2015 Jul;87(7):1184-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25676255</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2015 May;15(5):559-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25863564</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2015 Dec;87(12):2074-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26058920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2015 Aug;21(8):1422-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26196891</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2016 Mar 3;531(7592):114-117</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26855426</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2016 Mar 3;531(7592):118-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26935699</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2016 Dec 28;13(1):208</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28031027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Sci Tech. 2016 Dec;35(3):905-911</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28332641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2017 Jun 1;215(11):1702-1705</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28387845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2017 Apr 10;8:15092</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28393837</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2017 Jul;23(7):1079-1084</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28585916</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2017 Aug 21;45(14):e132</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28586438</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2017 Jun 21;6(6):e56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28634355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28807998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2018 Jan;90(1):184-190</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28817197</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diagn Microbiol Infect Dis. 2017 Oct;89(2):106-111</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28821364</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2017 Oct 25;92(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29070693</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Dec 11;12(12):e0189033</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29228016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2018 Apr 23;14(4):e1007009</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29684066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2018 Aug 13;14(8):e1007236</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30102747</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000598 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000598 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:30906787
   |texte=   Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:30906787" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.

Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki